Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Invested Capital (2020 - 2025)

Oncology Institute's Invested Capital history spans 6 years, with the latest figure at $61.7 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 36.23% year-over-year to $61.7 million; the TTM value through Dec 2025 reached $61.7 million, down 36.23%, while the annual FY2025 figure was $61.7 million, 36.23% down from the prior year.
  • Invested Capital reached $61.7 million in Q4 2025 per TOI's latest filing, down from $63.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $207.0 million in Q3 2022 to a low of $47.1 million in Q1 2021.
  • Average Invested Capital over 5 years is $114.5 million, with a median of $113.1 million recorded in 2024.
  • Peak YoY movement for Invested Capital: skyrocketed 364.01% in 2021, then crashed 44.58% in 2025.
  • A 5-year view of Invested Capital shows it stood at $104.2 million in 2021, then skyrocketed by 95.66% to $203.8 million in 2022, then fell by 29.41% to $143.9 million in 2023, then tumbled by 32.76% to $96.7 million in 2024, then plummeted by 36.23% to $61.7 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Invested Capital are $61.7 million (Q4 2025), $63.9 million (Q3 2025), and $66.0 million (Q2 2025).